Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.10 - Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
12:05 - 12:10 | Presenter: Jonathan Wade Goldman | Author(s): E. Angevin, J. Strickler, D. Ross Camidge, R. Heist, D. Morgensztern, M. Barve, H. Yue, J. Beaulieu, M. Motwani, D. Afar, L. Naumovski, Karen Kelly
- Abstract
Loading...
-
+
OA 07 - Biomarker for Lung Cancer
- 15:45 - 17:30
- 10/16/2017
- Location: Room 503
- Type: Oral
- Track: Biology/Pathology
- Moderators:Philip Christopher Mack, Shinichi Toyooka
-
+
OA 07.05 - Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms
16:40 - 16:50 | Presenter: Zofia Piotrowska | Author(s): K. Stirling, R. Heist, M.J. Mooradian, C. Rizzo, S.R. Digumarthy, M. Lanuti, F. Fintelmann, I.T. Lennes, A.F. Farago, Justin F Gainor, C.G. Azzoli, J. Temel, Mari Mino-Kenudson, D. Dias-Santagata, R. Corcoran, Alice Shaw, A.N. Hata, Lecia V Sequist
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf | Author(s): Ji-Youn Han, Makoto Nishio, P. Souquet, Luis Paz-Ares, F. De Marinis, Takashi Seto, M. De Jonge, T.M. Kim, Johan F. Vansteenkiste, Daniel SW Tan, Edward Brian Garon, H.J. Groen, Maximilian Johannes Hochmair, Enriqueta Felip, Noemi Reguart, M. Thomas, T.R. Overbeck, K. Ohashi, M. Giovannini, R. Yura, A. Joshi, M. Akimov, R. Heist
- Abstract
Loading...
-
+
OA 12 - Emerging Genomic Targets
- 11:00 - 12:30
- 10/18/2017
- Location: F203 + F204 (Annex Hall)
- Type: Oral
- Track: Advanced NSCLC
- Moderators:H. Akita, Maurice Pérol
-
+
OA 12.02 - Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions
11:10 - 11:20 | Presenter: Zofia Piotrowska | Author(s): D.B. Costa, M. Huberman, Geoffrey R. Oxnard, Justin F Gainor, R. Heist, I.T. Lennes, A. Muzikansky, Alice Shaw, C.G. Azzoli, Lecia V Sequist
- Abstract
Loading... -
+
OA 12.06 - Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
11:50 - 12:00 | Presenter: Alexander Drilon | Author(s): J.W. Clark, J. Weiss, Sai-Hong Ignatius Ou, D. Ross Camidge, Ben J Solomon, G. Otterson, L.C. Villaruz, Gregory J Riely, R. Heist, G.I. Shapiro, D.A. Murphy, Y. Liu, S.C. Wang, T. Usari, K.D. Wilner, Paul K. Paik
- Abstract
Loading...
-
+
OA 17 - Immunotherapy II
- 14:30 - 16:15
- 10/18/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Immunology and Immunotherapy
- Moderators:Yuichiro Ohe, Anne Tsao
-
+
OA 17.02 - Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC
14:40 - 14:50 | Presenter: Enric Carcereny | Author(s): Enriqueta Felip, Martin Reck, J. Patel, R. Heist, A. Balmanoukian, Laura Q Chow, Luis Paz-Ares, J. Qiu, S. Coleman, S. Mocci, A. Sandler, T. Kurata, Frances A Shepherd
- Abstract
Loading...